Total Payments
$447,617
2024 Payments
$97,923
Companies
10
Transactions
79
Medicare Patients
41
Medicare Billing
$1,883
Payment Breakdown by Category
Consulting$274,423 (61.3%)
Research$170,253 (38.0%)
Travel$1,773 (0.4%)
Food & Beverage$1,167 (0.3%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $274,423 | 34 | 61.3% |
| Unspecified | $170,253 | 21 | 38.0% |
| Travel and Lodging | $1,773 | 4 | 0.4% |
| Food and Beverage | $1,167 | 20 | 0.3% |
Payments by Type
General
$277,364
58 transactions
Research
$170,253
21 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novian Health Inc. | $175,214 | 23 | $0 (2022) |
| iCAD, Inc | $172,881 | 27 | $0 (2023) |
| Elekta, Inc. | $97,923 | 11 | $0 (2024) |
| Allergan Inc. | $590.00 | 4 | $0 (2017) |
| Focal Therapeutics, Inc. | $570.64 | 6 | $0 (2018) |
| Stryker Corporation | $148.85 | 2 | $0 (2019) |
| Genentech USA, Inc. | $129.92 | 1 | $0 (2018) |
| Medtronic USA, Inc. | $79.46 | 1 | $0 (2017) |
| ViiV Healthcare Company | $58.46 | 3 | $0 (2020) |
| Bayer HealthCare Pharmaceuticals Inc. | $21.39 | 1 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $97,923 | 11 | Elekta, Inc. ($97,923) |
| 2023 | $73,514 | 8 | iCAD, Inc ($73,514) |
| 2022 | $24,000 | 1 | Novian Health Inc. ($24,000) |
| 2021 | $120,740 | 14 | iCAD, Inc ($96,740) |
| 2020 | $24,080 | 7 | Novian Health Inc. ($24,000) |
| 2019 | $40,149 | 7 | Novian Health Inc. ($40,000) |
| 2018 | $24,214 | 5 | Novian Health Inc. ($24,000) |
| 2017 | $42,998 | 26 | Novian Health Inc. ($39,214) |
All Payment Transactions
79 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/22/2024 | Elekta, Inc. | FLEXITRON HDR (Device) | Consulting Fee | Cash or cash equivalent | $9,700.00 | General |
| Category: BRACHY SOLUTIONS | ||||||
| 10/25/2024 | Elekta, Inc. | FLEXITRON HDR (Device) | Consulting Fee | Cash or cash equivalent | $2,850.00 | General |
| Category: BRACHY SOLUTIONS | ||||||
| 10/04/2024 | Elekta, Inc. | FLEXITRON HDR (Device) | Consulting Fee | Cash or cash equivalent | $4,900.00 | General |
| Category: BRACHY SOLUTIONS | ||||||
| 10/04/2024 | Elekta, Inc. | FLEXITRON HDR (Device) | Consulting Fee | Cash or cash equivalent | $2,780.99 | General |
| Category: BRACHY SOLUTIONS | ||||||
| 08/26/2024 | Elekta, Inc. | FLEXITRON HDR (Device) | Consulting Fee | Cash or cash equivalent | $3,550.00 | General |
| Category: BRACHY SOLUTIONS | ||||||
| 07/19/2024 | Elekta, Inc. | FLEXITRON HDR (Device) | Consulting Fee | Cash or cash equivalent | $7,400.00 | General |
| Category: BRACHY SOLUTIONS | ||||||
| 06/27/2024 | Elekta, Inc. | FLEXITRON HDR (Device) | Consulting Fee | Cash or cash equivalent | $2,100.00 | General |
| Category: BRACHY SOLUTIONS | ||||||
| 05/09/2024 | Elekta, Inc. | FLEXITRON HDR (Device) | Consulting Fee | Cash or cash equivalent | $1,135.02 | General |
| Category: BRACHY SOLUTIONS | ||||||
| 05/09/2024 | Elekta, Inc. | FLEXITRON HDR (Device) | Consulting Fee | Cash or cash equivalent | $754.71 | General |
| Category: BRACHY SOLUTIONS | ||||||
| 04/26/2024 | Elekta, Inc. | FLEXITRON HDR (Device) | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
| Category: BRACHY SOLUTIONS | ||||||
| 01/04/2024 | Elekta, Inc. | — | Consulting Fee | Cash or cash equivalent | $60,952.50 | General |
| 09/22/2023 | iCAD, Inc | AXXENT SURFACE CONTROLLER (Device) | — | Cash or cash equivalent | $2,800.00 | Research |
| Study: Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab • Category: Oncology | ||||||
| 08/10/2023 | iCAD, Inc | AXXENT SURFACE CONTROLLER (Device) | — | Cash or cash equivalent | $23,769.90 | Research |
| Study: Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab • Category: Oncology | ||||||
| 07/25/2023 | iCAD, Inc | AXXENT SURFACE CONTROLLER (Device) | — | Cash or cash equivalent | $16,455.60 | Research |
| Study: Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab • Category: Oncology | ||||||
| 07/25/2023 | iCAD, Inc | AXXENT SURFACE CONTROLLER (Device) | — | Cash or cash equivalent | $4,200.00 | Research |
| Study: Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab • Category: Oncology | ||||||
| 07/25/2023 | iCAD, Inc | AXXENT SURFACE CONTROLLER (Device) | — | Cash or cash equivalent | $4,113.85 | Research |
| Study: Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab • Category: Oncology | ||||||
| 06/30/2023 | iCAD, Inc | AXXENT SURFACE CONTROLLER (Device) | — | Cash or cash equivalent | $20,374.20 | Research |
| Study: Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab • Category: Oncology | ||||||
| 06/30/2023 | iCAD, Inc | AXXENT SURFACE CONTROLLER (Device) | — | Cash or cash equivalent | $600.00 | Research |
| Study: Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab • Category: Oncology | ||||||
| 03/15/2023 | iCAD, Inc | AXXENT SURFACE CONTROLLER (Device) | — | Cash or cash equivalent | $1,200.00 | Research |
| Study: Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab • Category: Oncology | ||||||
| 08/11/2022 | Novian Health Inc. | — | Consulting Fee | Cash or cash equivalent | $24,000.00 | General |
| 12/03/2021 | iCAD, Inc | AXXENT SURFACE CONTROLLER (Device) | — | Cash or cash equivalent | $3,000.00 | Research |
| Study: Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab • Category: Oncology | ||||||
| 11/18/2021 | Novian Health Inc. | — | Consulting Fee | Cash or cash equivalent | $24,000.00 | General |
| 11/09/2021 | iCAD, Inc | AXXENT SURFACE CONTROLLER (Device) | — | Cash or cash equivalent | $9,000.00 | Research |
| Study: Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab • Category: Oncology | ||||||
| 10/06/2021 | iCAD, Inc | AXXENT SURFACE CONTROLLER (Device) | — | Cash or cash equivalent | $2,400.00 | Research |
| Study: Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab • Category: Oncology | ||||||
| 09/10/2021 | iCAD, Inc | AXXENT SURFACE CONTROLLER (Device) | — | Cash or cash equivalent | $7,000.00 | Research |
| Study: Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab • Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Phase II Study of Patients With Recurrent Glioblastoma Multiforme Treated With Maximal Safe Neurosurgical Resection and Intra-Operative Radiation Therapy (IORT) Using the Xoft Axxent Electronic Brachytherapy System and Bevacizumab | iCAD, Inc | $170,253 | 21 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2020 | 2 | 41 | 41 | $4,989 | $1,883 |
Total Patients
41
Total Services
41
Medicare Billing
$1,883
Procedure Codes
2
All Medicare Procedures & Services
2 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Office | 2020 | 23 | 23 | $2,415 | $1,358 | 56.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 18 | 18 | $2,574 | $524.99 | 20.4% |
About Dr. Barbara Schwartzberg, M.D
Dr. Barbara Schwartzberg, M.D is a Specialist healthcare provider based in Denver, Colorado. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1770547663.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Barbara Schwartzberg, M.D has received a total of $447,617 in payments from pharmaceutical and medical device companies, with $97,923 received in 2024. These payments were reported across 79 transactions from 10 companies. The most common payment nature is "Consulting Fee" ($274,423).
As a Medicare-enrolled provider, Schwartzberg has provided services to 41 Medicare beneficiaries, totaling 41 services with total Medicare billing of $1,883. Data is available for 1 year (2020–2020), covering 2 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Denver, CO
- Active Since 04/17/2006
- Last Updated 11/01/2010
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1770547663
Products in Payments
- AXXENT SURFACE CONTROLLER (Device) $170,253
- FLEXITRON HDR (Device) $36,971
- Axxent Controller (Device) $2,628
- ALLODERM (Device) $590.00
- BioZorb (Device) $570.64
- SURG - NEPTUNE (Device) $148.85
- PlasmaBlade (Device) $79.46
- DOVATO (Drug) $58.46
- Vitrakvi (Drug) $21.39
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Denver
Dr. Raymond Kim, Md, MD
Specialist — Payments: $3.7M
Specialist $3.7M
Dr. Anthony Canfield, M.d, M.D
Specialist — Payments: $953,125
Specialist $953,125
Dr. James Chappell, Md, MD
Specialist — Payments: $538,342
Specialist $538,342
Dr. Giancarlo Barolat-Romana, Md, MD
Specialist — Payments: $328,167
Specialist $328,167
Michael Schiff, M.d, M.D
Specialist — Payments: $244,233
Specialist $244,233
Mandeep Brar, M.d, M.D
Specialist — Payments: $102,895
Specialist $102,895